Navigation Links
Schizophrenia Drug Got Bad Rap
Date:7/13/2009

Less expensive clozapine might have saved thousands of lives, researchers say

MONDAY, July 13 (HealthDay News) -- Thousands of schizophrenia patients worldwide may have died because of safety restrictions on the use of the second-generation antipsychotic drug clozapine, a new study suggests.

Finnish researchers concluded that clozapine is associated with a lower death rate compared to other antipsychotics.

For this study, the researchers looked at the cause of death in about 67,000 schizophrenia patients in Finland between 1996 and 2006. They compared mortality rates associated with use of any psychotic drugs against no use of the drugs, and also compared mortality rates linked to the six most frequently used antipsychotic drugs with use of the first-generation antipsychotic perphenazine.

Although the use of second-generation antipsychotic drugs rose from 13 percent to 64 percent, the difference in life expectancy from age 20 between schizophrenia patients and the general population did not widen from 1996 (25 years) to 2006 (22.5 years).

Compared with current use of perphenazine, the highest risk for death was among patients taking quetiapine (41 percent higher) and the lowest was for clozapine (26 percent lower).

The study also found that long-term use (seven to 11 years) of antipsychotics in general is associated with about a 20 percent lower death rate than with no antipsychotic use.

The researchers said they were surprised that patients taking clozapine had the lowest death rate.

"Our results raise the issue of whether clozpaine should be used as a first-line treatment, because it seems to be the safest antipsychotic in terms of mortality and it is also the most effective," wrote Professor Jari Tiihonen, University of Kuopio and Niuvanniemi Hospital, and colleagues. "However, clozapine is inexpensive, and hence it is unprofitable for the pharmaceutical industry to market compared with other second-generation antipsychotic drugs. Additionally, monitoring schedules are a drawback that would be encountered with heightened use of clozapine, and physicians and other hospital staff might therefore be reluctant to initiate clozapine treatment."

The researchers suggest that restrictions on clozapine use were arbitrary. "Restrictions on use of clozapine and thioridazine have not been based on any evidence for their overall ratio of risk to benefit," Tiihonen wrote.

"Our results suggest that these instructions and recommendations [except for blood monitoring] might have caused thousands of premature deaths worldwide in patients who have been exposed to other antipsychotic drugs, which might be associated with increased mortality. In our opinion, such restrictions and recommendations should be based on solid scientific evidence for the safety of drugs. This example underscores the need for large nationwide databases to be used for surveillance of drug safety," they concluded.

The study appears online July 12 and in an upcoming print issue of The Lancet.

More information

Mental Health America has more about schizophrenia.



-- Robert Preidt



SOURCE: The Lancet, news release, July 12, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. International Collaboration led by Dr. Pablo V. Gejman,Researcher At NorthShore University HealthSystem's Research Institute, Finds Genetic Association of Schizophrenia to Chromosome 6p Variant
2. Possible Gene Regions for Schizophrenia Located
3. Schizophrenia Linked to Higher Risk of Dying From Cancer
4. Alterations in brains white matter key to schizophrenia, UCLA study shows
5. Study finds cancer is the second most frequent cause of death in individuals with schizophrenia
6. Animal model for schizophrenia identifies a novel approach for treating cognitive impairments
7. Pregnancy and the flu: A link to schizophrenia
8. Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
9. Schizophrenia does not increase risk of violent crime
10. Singing brains offers epilepsy and schizophrenia clues
11. New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Schizophrenia Drug Got Bad Rap
(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... receiving cognitive rehabilitation, according to a study released today at the 1st Pan ... rehabilitation programs are proven to be effective in improving cognitive function in PD ...
(Date:2/25/2017)... Viejo, CA (PRWEB) , ... February 25, 2017 , ... ... with ProSharpen Color tools from Pixel Film Studios. With ProSharpen Color users have total ... sliders to easily refine their color range. With color spectrum tools users can visually ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist , Dr. ... Antoine Dental Center. Currently, patients can get single dental implants for $3,599 and ... can learn more about these offers by contacting Antoine Dental Center. Both of ...
(Date:2/24/2017)... ... 2017 , ... WHAT: , The New Jersey Tech Council, ... as advocacy for the state and region‘s technology businesses, hosted their 2017 Innovation ... Innovation Forecast event highlights innovation throughout the region from small to large companies. ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The Global Wireless Health Market is poised to ... to reach approximately $330.5 billion by 2025. This industry ... segments on global as well as regional levels presented in the ...
(Date:2/24/2017)... , Feb. 24, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their offering. ... The Global Empty Capsules ... the next decade to reach approximately $2.9 billion by 2025. ... the given segments on global as well as regional levels presented in ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies ... eye market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Dry eye ...
Breaking Medicine Technology: